Sermorelin Acetate Australia: The Complete GHRH (1-29) Research Guide
Sermorelin acetate is a synthetic GHRH (1-29) analogue studied for its role in the growth hormone axis. This is a plain-English, education-first guide for Australian researchers, written by an Australian-owned supplier that has served Australian researchers for over three years. It is not medical, dosing or clinical advice.
What Is Sermorelin Acetate? GHRH (1-29) Explained
Sermorelin acetate is the acetate salt of sermorelin, a synthetic peptide that corresponds to the first 29 amino acids of human growth hormone-releasing hormone, commonly abbreviated GHRH. The naturally occurring GHRH molecule is a 44-amino-acid hormone released by the hypothalamus. Researchers established that the biologically active core of that molecule sits in its opening 29 residues, so the shortened GRF (1-29) fragment behaves as a fully functional GHRH analogue. This is why sermorelin appears in the literature interchangeably as GHRH (1-29) or GRF (1-29). If you are new to the growth hormone axis, that shared identity is the clearest place to begin.
Sermorelin, GRF (1-29) and GHRH (1-29) all refer to the same 29-amino-acid sequence. The words 'sermorelin acetate' simply denote the acetate salt form, which is the way the compound is most commonly stabilised as a lyophilised powder for laboratory storage. The historical pharmaceutical brand name for sermorelin was Geref.
Structurally, sermorelin is a short single-chain peptide with a molecular weight of roughly 3,358 for the free base. Presenting it as the acetate salt improves the stability and handling of the freeze-dried material, which matters for a compound with a short native lifespan in solution. Importantly, sermorelin is grouped with the other growth hormone secretagogues rather than with growth hormone itself. That distinction, secretagogue versus hormone, is central to how it is studied and is covered in detail below.
At NovaPeptides, sermorelin acetate is catalogued strictly as a research compound. Every reference to it on this page describes what it is investigated for in laboratory and research settings, not what it does for any person. It is supplied for research and educational use only.
How Sermorelin Is Studied to Work: The GHRH Receptor and the GH Axis
The studied sermorelin mechanism of action begins at the GHRH receptor, written GHRHR. This is a class B G-protein coupled receptor expressed on the somatotroph cells of the anterior pituitary. When sermorelin binds the GHRH receptor in research models, it activates the same intracellular cascade as endogenous GHRH: adenylate cyclase is stimulated, cyclic AMP rises, protein kinase A is engaged, and the somatotroph is prompted to synthesise and release stored growth hormone.
The signalling steps most often described for sermorelin in the literature
- Binding to the GHRH receptor on pituitary somatotroph cells
- Activation of adenylate cyclase and a rise in intracellular cyclic AMP
- Downstream protein kinase A signalling within the somatotroph
- Stimulation of the synthesis and pulsatile release of endogenous growth hormone
- Subsequent hepatic IGF-1 production as a downstream marker studied in the growth hormone axis
A defining feature of sermorelin in research is that it acts upstream, on the pituitary, rather than supplying growth hormone directly. Because of this, investigators are interested in the fact that it operates within the body's own regulatory circuitry. The pituitary still answers to somatostatin, the inhibitory brake on growth hormone release, so the natural pulsatile pattern and negative feedback of the axis remain part of the model. This is often contrasted in the literature with exogenous recombinant growth hormone, which bypasses that upstream control entirely.
A growth hormone secretagogue is a compound studied for its ability to prompt the body's own pituitary to release growth hormone. That is mechanistically distinct from administering growth hormone as a hormone. This upstream, feedback-preserving mode of action is the main reason sermorelin has drawn sustained research interest.
What Sermorelin Acetate Is Researched For
Sermorelin is studied almost entirely in the context of the somatotropic, or growth hormone, axis. The research areas below describe questions investigators have explored in laboratory, animal and clinical research settings. They are descriptions of scientific interest, not claims about outcomes for any individual.
Research areas associated with sermorelin (GHRH 1-29)
- Regulation of the growth hormone axis and how the pituitary responds to GHRH signalling
- Growth hormone secretion dynamics, including the pulsatility of GH release
- Downstream IGF-1 signalling as a measurable marker of axis activity
- The age-related decline in growth hormone output, described in the literature as somatopause
- Historical use as a provocative agent in GHRH stimulation testing to study pituitary reserve and growth hormone deficiency
- Sleep architecture research, given the established links between GHRH signalling and slow-wave sleep
- Body composition research models that track the growth hormone and IGF-1 axis
- Comparative pharmacology of GHRH analogues and growth hormone secretagogues
It is worth being precise here. Sermorelin is a tool that researchers use to probe how the growth hormone axis behaves, and its long history as a diagnostic agent reflects that role. NovaPeptides makes no therapeutic, cosmetic or performance claim about the compound. We would rather give you an accurate map of the research landscape than an inflated one.
Sermorelin is studied as a way to interrogate the body's own growth hormone signalling, not as a substitute for it.
Sermorelin vs CJC-1295, Tesamorelin and the GHRPs
Sermorelin sits within a family of GHRH analogues, and understanding its neighbours makes the research clearer. Tesamorelin is a stabilised GHRH analogue studied along similar receptor lines. CJC-1295 is a modified GHRH analogue that exists in two research forms, one with a drug affinity complex (DAC) that binds albumin to extend its lifespan and one without. All three engage the GHRH receptor pathway described above.
A separate class, the growth hormone releasing peptides or GHRPs, includes ipamorelin, GHRP-2, GHRP-6 and hexarelin. These act on a different receptor entirely, the growth hormone secretagogue receptor (GHSR), which is the ghrelin receptor. Because GHRH analogues and GHRPs work through two complementary receptor systems, they are frequently studied together in the research literature, where their effects on growth hormone release can be additive.
How sermorelin compares within the secretagogue landscape
- Sermorelin (GHRH 1-29): the classic short-acting GHRH analogue, the reference point for the family
- CJC-1295 with DAC: a GHRH analogue engineered for a much longer research half-life via albumin binding
- Tesamorelin: a stabilised GHRH analogue studied with the same receptor mechanism
- Ipamorelin, GHRP-2, GHRP-6: GHRPs that act on the separate ghrelin receptor and are often paired with a GHRH analogue in research
- The shared theme: all are secretagogues studied for stimulating the pituitary rather than replacing growth hormone
Research combining a GHRH analogue such as sermorelin with a GHRP such as ipamorelin is common because the two act on distinct receptors. Investigators study whether engaging both pathways at once produces a larger response than either alone. This is a research observation about receptor pharmacology, not a protocol or a recommendation.
The Sermorelin Research Landscape: Half-Life and DPP-4 Sensitivity
One of the most studied practical characteristics of sermorelin is its short circulating half-life, generally reported at roughly 10 to 20 minutes. In solution the peptide is degraded quickly by enzymes, most notably dipeptidyl peptidase-4, abbreviated DPP-4, which cleaves residues from the N-terminus of the chain. This rapid breakdown is not a flaw so much as a defining feature of the native GHRH sequence, and it shapes how the compound behaves in any research model.
This short half-life is precisely why later GHRH analogues were engineered. CJC-1295 with DAC was designed to bind albumin and dramatically extend its research half-life, while tesamorelin was stabilised against enzymatic cleavage. Sermorelin remains the reference molecule against which these longer-acting analogues are compared, and its rapid, transient action is itself a subject of study, particularly for research interested in mimicking the natural, short-lived pulses of GHRH signalling.
For research design, the DPP-4 sensitivity and short half-life are important variables. They influence assay timing, model selection and how the growth hormone response is measured. These are the kinds of parameters that a well-documented Certificate of Analysis and a clear understanding of the peptide help a researcher plan around.
Handling Sermorelin Acetate in a Research Setting
Sermorelin acetate is supplied as a lyophilised, or freeze-dried, powder in a sealed vial, with the milligram mass of peptide stated on the accompanying Certificate of Analysis. The notes below describe general laboratory handling practice for peptides of this type. They are provided for context only and are not a protocol, and nothing here refers to use in or on any person.
General laboratory handling notes for a peptide such as sermorelin
- Freeze-dried peptide is typically kept frozen and protected from light and moisture until it is needed
- Reconstitution with bacteriostatic water is standard laboratory practice for research peptides in solution
- Once reconstituted, peptides in solution are generally refrigerated and used within a limited window
- Repeated freeze and thaw cycles are usually minimised because they can degrade peptide integrity
- The known DPP-4 sensitivity and short half-life of sermorelin are relevant variables to account for in in vitro and in vivo model design
- Sterile technique and validated model systems are assumed throughout any research handling
The points above describe how a research compound of this class is generally stored and prepared in a laboratory. They are not dosing guidance, not a method for any individual, and not an endorsement of human use. Sermorelin acetate from NovaPeptides is for laboratory and research use only.
Sourcing and Verification: The Novagen Certificate of Analysis
With research peptides, the single most important question is whether the material in the vial is genuinely what the label says it is. That is answered by an independent Certificate of Analysis, or COA. Every batch of sermorelin acetate supplied by NovaPeptides carries a Novagen Laboratories Certificate of Analysis, and each COA can be checked against a unique key so you can confirm the document is real rather than taking a supplier's word for it.
What to look for on a sermorelin Certificate of Analysis
- Identity confirmation, typically by mass spectrometry, verifying the correct 29-amino-acid sequence and molecular weight
- Purity, usually reported as a percentage by high performance liquid chromatography (HPLC)
- The specific batch or lot number that ties the document to the vial in hand
- The tested compound named clearly as sermorelin or GHRH (1-29)
- A verifiable reference or key that lets you confirm the certificate independently
A COA that you cannot independently verify is little more than a printout. The reason NovaPeptides pairs every batch with a Novagen certificate and a verification key is so that Australian researchers can trust the identity and purity of the material before it enters any research model. Purity and identity are the foundation of reproducible results.
Why Australian Researchers Choose NovaPeptides for Sermorelin
NovaPeptides is an Australian-owned business based on the Gold Coast that has supplied research peptides to Australian researchers for over three years. That track record matters in a field where consistency, documentation and reliable supply are not guaranteed. The priority is simple: accurately identified, independently tested material, described honestly.
What sets the NovaPeptides sermorelin supply apart
- A Novagen Laboratories Certificate of Analysis on every single batch, with a unique key you can verify yourself
- Australian owned and Gold Coast based, with local supply to Australian researchers
- Over three years of continuous supply to the Australian research community
- Honest, education-first information with no therapeutic or performance claims
- Clear research-use-only positioning that respects Australian regulatory boundaries
The aim is not to make sermorelin sound like more than it is. It is a well-characterised research peptide with a long scientific history, and it is supplied here with the documentation a serious researcher expects.
Sermorelin Acetate in Australia: Research-Use-Only and Regulatory Status
Sermorelin acetate supplied by NovaPeptides is for laboratory and research use only. It is not approved by the Therapeutic Goods Administration (TGA) for human use, it is not a medicine, and it is not supplied for consumption, injection or any personal application. It is intended for qualified research and educational purposes.
Sermorelin does have a regulatory history worth understanding in context. Overseas, it was previously approved and marketed as a diagnostic and therapeutic agent under the brand name Geref before being discontinued as a commercial product. That is history, and it is not the current Australian position. In Australia today, the material offered here is positioned strictly as a research compound and nothing more.
Sermorelin acetate from NovaPeptides is not TGA approved for human use and is supplied for laboratory and research use only. Nothing on this page is medical, dosing or clinical advice, and nothing here is a claim of safety, efficacy or benefit for any person.
Frequently asked questions
What is sermorelin acetate?+
Sermorelin acetate is the acetate salt of sermorelin, a synthetic peptide corresponding to the first 29 amino acids of human growth hormone-releasing hormone (GHRH). Because the active core of the 44-residue GHRH hormone sits in those opening 29 residues, sermorelin is a functional GHRH analogue and is written interchangeably as GHRH (1-29) or GRF (1-29). At NovaPeptides it is supplied for research and educational use only, with a verifiable Novagen Certificate of Analysis on every batch.
What is the sermorelin mechanism of action?+
The studied sermorelin mechanism of action centres on the GHRH receptor (GHRHR) found on the somatotroph cells of the anterior pituitary. Binding activates adenylate cyclase, raises cyclic AMP and engages protein kinase A, which prompts the pituitary to synthesise and release its own stored growth hormone. Sermorelin therefore acts upstream, as a secretagogue that works within the body's own regulatory loop, rather than supplying growth hormone directly.
What is GHRH (1-29) and how does it relate to sermorelin?+
GHRH (1-29), also written GRF (1-29), is the name for the first 29 amino acids of growth hormone-releasing hormone. Sermorelin is exactly that sequence made synthetically. In other words, sermorelin and GHRH (1-29) are the same molecule described two ways: sermorelin is the compound name and GHRH (1-29) describes which part of the natural hormone it represents.
What is sermorelin studied for?+
In research settings sermorelin is studied in the context of the growth hormone axis: how the pituitary responds to GHRH signalling, the dynamics and pulsatility of growth hormone release, downstream IGF-1 signalling, the age-related decline in growth hormone output described as somatopause, and historically as a provocative agent in GHRH stimulation testing. These are descriptions of scientific research interest, not claims of benefit for any person.
What is the difference between sermorelin and CJC-1295?+
Both are GHRH analogues that engage the same GHRH receptor pathway, but they differ in duration. Sermorelin has a short research half-life of roughly 10 to 20 minutes. CJC-1295, particularly the form with a drug affinity complex (DAC), was engineered to bind albumin and greatly extend its half-life. Sermorelin is the classic short-acting reference molecule, while CJC-1295 with DAC represents a long-acting evolution of the same idea.
What is the half-life of sermorelin?+
Sermorelin has a short circulating half-life, generally reported at around 10 to 20 minutes. It is degraded quickly in solution by enzymes, most notably dipeptidyl peptidase-4 (DPP-4), which cleaves residues from the N-terminus. This rapid, transient action is a defining feature of the native GHRH sequence and is one reason longer-acting analogues such as CJC-1295 with DAC and tesamorelin were later developed.
Is sermorelin the same as HGH?+
No. HGH, or human growth hormone, is the hormone itself. Sermorelin is a growth hormone secretagogue: a GHRH analogue studied for its ability to prompt the pituitary to release the body's own growth hormone. The distinction matters because sermorelin acts upstream and keeps the natural feedback and pulsatile control of the axis in the picture, whereas exogenous growth hormone bypasses that control. This comparison is a research description, not a recommendation.
Why is sermorelin often researched alongside GHRPs like ipamorelin?+
Sermorelin is a GHRH analogue that acts on the GHRH receptor, while GHRPs such as ipamorelin, GHRP-2 and GHRP-6 act on a separate receptor, the growth hormone secretagogue (ghrelin) receptor. Because the two classes work through complementary pathways, researchers frequently study them together to observe whether engaging both receptors produces an additive growth hormone response. This is an observation about receptor pharmacology, not a protocol.
How is sermorelin acetate supplied and handled in a research setting?+
It is supplied as a lyophilised (freeze-dried) powder in a sealed vial, with the peptide mass stated on the Certificate of Analysis. In general laboratory practice, freeze-dried peptide is kept frozen and protected from light, reconstituted with bacteriostatic water for research use, then refrigerated and used within a limited window while minimising freeze and thaw cycles. These are general handling notes for context only, not dosing guidance or a method for any person.
Is sermorelin legal and TGA approved in Australia?+
Sermorelin acetate from NovaPeptides is supplied for laboratory and research use only and is not approved by the TGA for human use. It is not a medicine and is not supplied for consumption or personal application. Overseas it was previously marketed as a diagnostic agent under the brand name Geref before being discontinued, but that is regulatory history and not the current Australian position, where it is positioned strictly as a research compound.
Does NovaPeptides provide a Certificate of Analysis for sermorelin?+
Yes. Every batch of sermorelin acetate carries an independent Novagen Laboratories Certificate of Analysis, and each certificate can be checked against a unique key so you can confirm it is genuine. A typical COA reports identity by mass spectrometry, purity by HPLC and the batch number that ties the document to the vial. NovaPeptides is Australian owned, Gold Coast based, and has supplied research peptides to Australian researchers for over three years.
Questions? Talk to us.
Message us on WhatsApp and we will walk you through the kits, the COAs, reconstitution and the dose tool.
Chat with us on WhatsApp